Results 81 to 90 of about 1,026 (172)

Quality of life improves during antiviral therapy with bulevirtide

Zeitschrift für Gastroenterologie
Abstract Hepatitis D virus (HDV) infection is the most severe form of viral hepatitis and has been shown to be associated with reduced quality of life. With the approval of the entry inhibitor bulevirtide, the first specific agent for HDV infection became available.
Eichholz, Julia Carolin, Dietz-Fricke, Christopher, Mrowietz, Simon Kristian, Dinkelborg, Katja, Port, Kerstin, Wedemeyer, Heiner, Deterding, Katja   +6 more
openaire   +2 more sources

State-of-the-art and emerging antivirals for chronic hepatitis B infection

, 2022
Introduction: Current treatment options for chronic hepatitis B virus (HBV) infection cannot achieve functional cure [hepatitis B surface antigen (HBsAg) loss]; therefore, new approaches are under investigation.
Papatheodoridis, G.V., Papatheodoridi, M.   +1 more
core   +1 more source

144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial

Background & aims: Bulevirtide 2 mg/day is approved in Europe, Australia, Russia, and Canada for treatment of compensated chronic hepatitis D (CHD). However, long-term outcomes after treatment discontinuation are unknown.
Schulze Zur Wiesch, Julian, Osinusi, Anu, Aleman, Soo, Brunetto, Maurizia Rossana, Lampertico, Pietro, Blank, Antje, Geyvandova, Natalia, Morozov, Viacheslav, Arterburn, Sarah, Sagalova, Olga, Lichtman, Amos, Wedemeyer, Heiner, Mamonova, Nina, Stepanova, Tatiana, Andreone, Pietro, Christian-Cox, Florence, Bogomolov, Pavel, Chulanov, Vladimir, Berger, Annemarie, Ciesek, Sandra, Tseng, Steve, Manuilov, Dmitry, Mercier, Renee-Claude, Cornberg, Markus, Zeuzem, Stefan, Aleman, S,, Wedemeyer, H, Chulanov, V, Geyvandova, N, Bogomolov, P, Blank, A, Sagalova, O, Andreone, P, Mamonova, N, Morozov, V   +34 more
core   +1 more source

Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations

JHEP Reports
Background & Aims: Bulevirtide (BLV) was approved for the treatment of compensated chronic hepatitis D virus (HDV) infection in Europe in 2020. However, research into the effects of the entry inhibitor BLV on HDV-host dynamics is in its infancy ...
Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Floriana Facchetti, Ferruccio Ceriotti, Pietro Lampertico, Harel Dahari   +11 more
doaj   +1 more source

Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment

Journal of Virology
Chronic hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. Although humans produce 12 subtypes of interferon-alpha (IFN-α), IFN-α2a has been the only commonly used treatment against HDV.
Yibo Ding, Qiudi Li, Yunlu Sha, Ruilin Si, Chengqian Feng, Mei Liu, Zhanghao Feng, Xutong Ding, Ying Li, Huiyuan Fu, Shiquan Liang, Qili Yao, Zhenfeng Zhang, Feng Li, Stephan Urban, Hongbo Guo, Wenshi Wang   +16 more
doaj   +1 more source

P37 | Bulevirtide treatment for chronic HDV hepatitis: single-center experience

Italian Journal of Medicine
Premises and Purpose of the study: HDV is a RNA virus that uses HBsAg as own viral envelope and is estimated to infect about 15-20 million persons worldwide. Bulevirtide (BLV) is a novel therapy for chronic HDV infection that binds the NCTP receptor and
doaj   +1 more source

The cost-effectiveness of increasing hepatitis Delta testing for individuals co-infected with HBV and HIV in the Netherlands

International Journal of Infectious Diseases
Objectives: Chronic hepatitis D virus (HDV) infection accelerates liver‐related morbidity and mortality in people living with HIV and hepatitis B virus (HBV). In the Netherlands, HDV testing among HIV/HBV-coinfected adults is currently limited.
Shyevon Marchena, Mehlika Toy
doaj   +1 more source

Clinical Pharmacology of Bulevirtide: Focus on Known and Potential Drug–Drug Interactions

Pharmaceutics
Background: Hepatitis D virus (HDV) is a defective virus requiring co-infection with hepatitis B virus (HBV) to replicate, occurring in 5% of HBV+ patients.
Martina Billi, Sara Soloperto, Stefano Bonora, Antonio D’Avolio, Amedeo De Nicolò   +4 more
doaj   +1 more source

Bulevirtide for Chronic Hepatitis Delta

Gastroenterology, 2023
openaire   +3 more sources

The Culprit Behind HBV-Infected Hepatocytes: NTCP

Drug Design, Development and Therapy
Shenghao Li,1,2,* Liyuan Hao,1,2,* Jiali Deng,1,2 Junli Zhang,3 Fei Yu,1,2 Fanghang Ye,1,2 Na Li,1,2 Xiaoyu Hu2 1School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People’s Republic of ...
Li S, Hao L, Deng J, Zhang J, Yu F, Ye F, Li N, Hu X   +7 more
doaj